CALL - SPRINTER OPEN END - BIOGEN IDEC | Market Closed - Deutsche Boerse AG 01:43:50 2024-06-05 pm EDT | ||
| 6.74 EUR | +6.81% |
|
| Current month | +19.72% | ||
| 1 month | +36.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 6.74 | +6.81% |
| 24-06-04 | 6.31 | +1.94% |
| 24-06-03 | 6.19 | +9.95% |
| 24-05-31 | 5.63 | +11.71% |
| 24-05-30 | 5.04 | +5.88% |
Delayed Quote Deutsche Boerse AG
Last update June 05, 2024 at 01:43 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VV3XT2 |
| ISIN | DE000VV3XT20 |
| Date issued | 2022-06-17 |
| Strike | 166.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.03 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.13 € |
|---|---|
| Lowest since issue | 2.55 € |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
236.7
USD
Average target price
284.8
USD
Spread / Average Target
+20.30%
- Stock Market
- Certificates
- Certificat
